Fig. 1: TROP2 and TACSTD2 expression in breast cancer. | npj Breast Cancer

Fig. 1: TROP2 and TACSTD2 expression in breast cancer.

From: Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan

Fig. 1

A Breast cancer FFPE sections were assessed for TROP2 expression by IHC. Representative images demonstrate no TROP2expression (top left, H-score 0), low TROP2 expression (top right, H-score 57), medium TROP2 expression (bottom left, H-score 140), and high TROP2 expression (bottom right, H-score 290). B TROP2 positivity in breast cancer when stratified by histologic subtype. Of 41 cases evaluated, only 2 of 5 (40%) of metaplastic breast cases were TROP2 positive. C TROP2 expression in TMA of 106 breast tumors. Of the 97 non-metaplastic cases, 2 (2.1%) were TROP2 negative, 42 had low TROP2 expression (43.3%), 42 had medium TROP2 expression, and 11 had high TROP2 expression. Of the 9 metaplastic cases, 5 (55.6%) had no TROP2 expression, 3 (33.3%) had low TROP2 expression, and 1 (11.1%) had high TROP2 expression. D Comparison of TACSTD2 expression in metaplastic vs. non-metaplastic breast tumors in TCGA. Expression of TACSTD2 was higher in non-metaplastic tumors (p < 0.001, t-test).

Back to article page